KRT80

Summary

KRT80 (keratin 80, HGNC:27056) is a protein-coding gene on chromosome 12q13.13, encoding Keratin, type II cytoskeletal 80 (Q6KB66).

Keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells and are subdivided into epithelial keratins and hair keratins. This gene’s expression profile shows that it encodes a type II epithelial keratin, although structurally the encoded protein is more like a type II hair keratin. This protein is involved in cell differentiation, localizing near desmosomal plaques in earlier stages of differentiation but then dispersing throughout the cytoplasm in terminally differentiating cells. The type II keratins are clustered in a region of chromosome 12q13. Two transcript variants encoding two different fully functional isoforms have been found for this gene.

Source: NCBI Gene 144501 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 94 total
• MANE Select transcript: NM_182507

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:27056
Approved symbol	KRT80
Name	keratin 80
Location	12q13.13
Locus type	gene with protein product
Status	Approved
Aliases	KB20
Ensembl gene	ENSG00000167767
Ensembl biotype	protein_coding
OMIM	611161
Entrez	144501

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding, 1 retained_intron

ENST00000313234, ENST00000394815, ENST00000466011

RefSeq mRNA: 2 — MANE Select: NM_182507 NM_001081492, NM_182507

CCDS: CCDS41784, CCDS8821

Canonical transcript exons

ENST00000394815 — 9 exons

Exon	Start	End
ENSE00001116720	52168996	52171522
ENSE00001483454	52180513	52180608
ENSE00001483459	52180903	52180963
ENSE00001483465	52185379	52185587
ENSE00003461804	52173038	52173163
ENSE00003499509	52173600	52173764
ENSE00003654267	52171658	52171713
ENSE00003673883	52172198	52172418
ENSE00003846194	52191603	52192014

Expression profiles

Bgee: expression breadth ubiquitous, 170 present calls, max score 98.09.

FANTOM5 (CAGE): breadth broad, TPM avg 29.9373 / max 1318.7522, expressed in 545 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
131003	24.7217	490
131002	3.8893	405
131000	0.3738	149
131001	0.3618	213
206708	0.1501	76
131004	0.1368	81
130996	0.1001	57
130998	0.0859	45
130999	0.0808	35
130997	0.0370	22

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skin of abdomen	UBERON:0001416	98.09	gold quality
upper arm skin	UBERON:0004263	97.65	gold quality
skin of leg	UBERON:0001511	97.49	gold quality
zone of skin	UBERON:0000014	97.11	gold quality
lower esophagus mucosa	UBERON:0035834	96.91	gold quality
upper leg skin	UBERON:0004262	95.52	gold quality
amniotic fluid	UBERON:0000173	95.04	gold quality
skin of hip	UBERON:0001554	91.08	gold quality
gingiva	UBERON:0001828	90.75	gold quality
gingival epithelium	UBERON:0001949	90.63	gold quality
esophagus mucosa	UBERON:0002469	90.30	gold quality
mammalian vulva	UBERON:0000997	89.33	gold quality
penis	UBERON:0000989	89.28	gold quality
esophagus squamous epithelium	UBERON:0006920	88.19	gold quality
buccal mucosa cell	CL:0002336	87.46	gold quality
oral cavity	UBERON:0000167	87.23	gold quality
islet of Langerhans	UBERON:0000006	86.79	gold quality
palpebral conjunctiva	UBERON:0001812	86.13	gold quality
parotid gland	UBERON:0001831	85.91	gold quality
mouth mucosa	UBERON:0003729	85.67	gold quality
minor salivary gland	UBERON:0001830	85.39	gold quality
saliva-secreting gland	UBERON:0001044	85.16	gold quality
epithelial cell of pancreas	CL:0000083	84.26	silver quality
tonsil	UBERON:0002372	82.84	gold quality
nipple	UBERON:0002030	82.72	gold quality
vagina	UBERON:0000996	82.16	gold quality
pharyngeal mucosa	UBERON:0000355	81.85	gold quality
pancreas	UBERON:0001264	79.17	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	78.43	gold quality
sperm	CL:0000019	78.16	silver quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-7249	yes	11.12
E-ANND-3	yes	5.38
E-CURD-10	no	532.88
E-GEOD-86618	no	180.70

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

91 targeting KRT80, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-221-5P	99.86	65.45	1052
HSA-MIR-8073	99.86	65.21	1118
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-10394-5P	99.65	66.83	1852
HSA-MIR-1205	99.65	66.76	1826
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-6134	99.63	65.68	1537
HSA-MIR-9851-3P	99.63	69.68	1110
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084

Literature-anchored findings (GeneRIF, showing 8)

• Alternative splice variants, K80 and K80.1 distribute differently in epithelia of hair and skin. (PMID:20843789)
• KRT80 was an independent prognostic biomarker for CRC and promoted CRC migration and invasion by interacting with PRKDC via activation of the AKT pathway. (PMID:30262880)
• Study demonstrated that the type II keratin topological associating domain undergoes epigenetic reprogramming in aromatase inhibitors-resistant ER-alpha positive breast cancer cells, leading to KRT80 upregulation. KRT80 expression is driven by de novo enhancer activation by SREBP1. KRT80 levels correlate with stiffer tumors and associates with poor survival in ER-alpha positive breast cancer patients. (PMID:31073170)
• MiR-4268 suppresses gastric cancer genesis through inhibiting keratin 80. (PMID:35748914)
• KRT80 expression works as a biomarker and a target for differentiation in gastric cancer. (PMID:37129345)
• Characters of KRT80 and its roles in neoplasms diseases. (PMID:37211956)
• LINC01485 contributes to colorectal cancer progression by targeting miR-383-5p/KRT80 axis. (PMID:37782686)
• The facilitating effects of KRT80 on chemoresistance, lipogenesis, and invasion of esophageal cancer. (PMID:38241178)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Krt80	ENSMUSG00000037185
rattus_norvegicus	Krt80	ENSRNOG00000025994

Paralogs (68): KRT33A (ENSG00000006059), VIM (ENSG00000026025), KRT31 (ENSG00000094796), NEFM (ENSG00000104722), KRT23 (ENSG00000108244), KRT37 (ENSG00000108417), KRT32 (ENSG00000108759), KRT18 (ENSG00000111057), LMNB1 (ENSG00000113368), KRT36 (ENSG00000126337), KRT17 (ENSG00000128422), GFAP (ENSG00000131095), KRT34 (ENSG00000131737), KRT33B (ENSG00000131738), NES (ENSG00000132688), PRPH (ENSG00000135406), KRT85 (ENSG00000135443), KRT7 (ENSG00000135480), KRT71 (ENSG00000139648), INA (ENSG00000148798), LMNTD1 (ENSG00000152936), LMNA (ENSG00000160789), KRT84 (ENSG00000161849), KRT82 (ENSG00000161850), KRT1 (ENSG00000167768), KRT24 (ENSG00000167916), KRT8 (ENSG00000170421), KRT78 (ENSG00000170423), KRT86 (ENSG00000170442), KRT75 (ENSG00000170454), KRT6C (ENSG00000170465), KRT4 (ENSG00000170477), KRT74 (ENSG00000170484), KRT72 (ENSG00000170486), KRT83 (ENSG00000170523), BFSP2 (ENSG00000170819), KRT19 (ENSG00000171345), KRT15 (ENSG00000171346), KRT38 (ENSG00000171360), KRT13 (ENSG00000171401)

Protein

Protein identifiers

Keratin, type II cytoskeletal 80 — Q6KB66 (reviewed: Q6KB66)

Alternative names: Cytokeratin-80, Keratin-80, Type-II keratin Kb20

All UniProt accessions (1): Q6KB66

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Heterotetramer of two type I and two type II keratins.

Tissue specificity. Weakly expressed in tongue, but not skin or in any other tissues or organs examined.

Miscellaneous. There are two types of cytoskeletal and microfibrillar keratin, I (acidic) and II (neutral to basic) (40-55 and 56-70 kDa, respectively).

Similarity. Belongs to the intermediate filament family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q6KB66-1	1	yes
Q6KB66-2	2
Q6KB66-3	3

RefSeq proteins (2): NP_001074961, NP_872313* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003054	Keratin_II	Family
IPR039008	IF_rod_dom	Domain

Pfam: PF00038

UniProt features (18 total): region of interest 8, splice variant 3, modified residue 2, chain 1, domain 1, site 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6KB66-F1	76.93	0.56

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 334 (stutter)

Post-translational modifications (2): 45, 396

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-6805567	Keratinization
R-HSA-6809371	Formation of the cornified envelope
R-HSA-1266738	Developmental Biology

MSigDB gene sets: 129 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_UP, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_INTERMEDIATE_FILAMENT_BASED_PROCESS, GOBP_INTERMEDIATE_FILAMENT_ORGANIZATION, SENESE_HDAC1_AND_HDAC2_TARGETS_DN, GOBP_EPIDERMAL_CELL_DIFFERENTIATION, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, GATA3_01, GOBP_EPIDERMIS_DEVELOPMENT, TGAGATT_MIR216, BASAKI_YBX1_TARGETS_UP, GOBP_KERATINIZATION, CERVERA_SDHB_TARGETS_1_UP, GOCC_CELL_CELL_JUNCTION

GO Biological Process (2): keratinization (GO:0031424), intermediate filament organization (GO:0045109)

GO Molecular Function (2): structural constituent of skin epidermis (GO:0030280), protein binding (GO:0005515)

GO Cellular Component (5): cytoplasm (GO:0005737), cytosol (GO:0005829), intermediate filament (GO:0005882), keratin filament (GO:0045095), intermediate filament cytoskeleton (GO:0045111)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Developmental Biology	1
Keratinization	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
keratinocyte differentiation	1
multicellular organismal process	1
intermediate filament cytoskeleton organization	1
supramolecular fiber organization	1
structural molecule activity	1
binding	1
intracellular anatomical structure	1
cytoplasm	1
intermediate filament cytoskeleton	1
polymeric cytoskeletal fiber	1
intermediate filament	1
cytoskeleton	1

Protein interactions and networks

STRING

965 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KRT80	TINCR	A0A2R8Y7D0	639
KRT80	CDSN	Q15517	532
KRT80	KRTAP3-1	Q9BYR8	530
KRT80	TGM3	Q08188	519
KRT80	KRTDAP	P60985	513
KRT80	CNFN	Q9BYD5	503
KRT80	SOWAHA	Q2M3V2	458
KRT80	PIERCE1	Q5BN46	447
KRT80	STAU1	O95793	408
KRT80	ALOX12B	O75342	400
KRT80	CFTR	P13569	386
KRT80	C11orf86	A6NJI1	386
KRT80	CRNN	Q9UBG3	384
KRT80	MLANA	Q16655	384
KRT80	KRTAP15-1	Q3LI76	367
KRT80	LCE2D	Q5TA82	367

IntAct

35 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
MEOX2	KRT80	psi-mi:“MI:0915”(physical association)	0.560
KRT15	KRT80	psi-mi:“MI:0915”(physical association)	0.560
KRT80	KRT20	psi-mi:“MI:0915”(physical association)	0.560
KRT80	MEOX2	psi-mi:“MI:0915”(physical association)	0.560
KRT20	KRT80	psi-mi:“MI:0915”(physical association)	0.560
KRT80	KRT15	psi-mi:“MI:0915”(physical association)	0.560
rep	KRT80	psi-mi:“MI:0915”(physical association)	0.490
METTL14	HMGB1P1	psi-mi:“MI:0914”(association)	0.350
TANK	CNOT1	psi-mi:“MI:0914”(association)	0.350
TRAF2	TMEM178B	psi-mi:“MI:0914”(association)	0.350
COPS5	FBLL1	psi-mi:“MI:0914”(association)	0.350
LRRK2		psi-mi:“MI:0914”(association)	0.350
RNLS	STATH	psi-mi:“MI:0914”(association)	0.350
STYX	BANF1	psi-mi:“MI:0914”(association)	0.350
BMI1	MEIS3P1	psi-mi:“MI:0914”(association)	0.350
GABARAPL2		psi-mi:“MI:0914”(association)	0.350
KRT80	CYP17A1	psi-mi:“MI:0914”(association)	0.350
SULF2	HNRNPCL1	psi-mi:“MI:0914”(association)	0.350
SULF2	IGHA1	psi-mi:“MI:0914”(association)	0.350
LGALS3BP	IGHV3-64D	psi-mi:“MI:0914”(association)	0.350

BioGRID (70): KRT80 (Two-hybrid), KRT80 (Two-hybrid), KRT80 (Two-hybrid), KRT80 (Affinity Capture-MS), KRT80 (Affinity Capture-MS), KRT80 (Affinity Capture-MS), KRT80 (Affinity Capture-MS), KRT80 (Affinity Capture-MS), KRT80 (Affinity Capture-MS), KRT80 (Affinity Capture-MS), KRT80 (Affinity Capture-MS), KRT80 (Affinity Capture-MS), KRT80 (Affinity Capture-MS), KRT80 (Affinity Capture-MS), KRT80 (Affinity Capture-MS)

ESM2 similar proteins: A0JND2, A3KN27, A6BLY7, A6H712, A6QNX5, A6QQJ3, A7YWK3, D3ZER2, E1AB55, O76014, O76015, P08552, P15331, P21807, P35617, P41219, P46660, P48670, Q0VBK2, Q13515, Q148H5, Q148H6, Q148H8, Q14CN4, Q28177, Q3SY84, Q3TRJ4, Q6A162, Q6IFW3, Q6IFW8, Q6IFX0, Q6IFX4, Q6IFZ9, Q6IG04, Q6IME9, Q6IMF1, Q6KB66, Q6NVD9, Q6NXH9, Q7RTS7

Diamond homologs: A0A125S9M6, A0JND2, A4FUZ0, A5A6M8, A6NCN2, A7YWK3, O43790, P02542, P02545, P02547, P02548, P04104, P04260, P04261, P04262, P04263, P07196, P07744, P08551, P08928, P09010, P10999, P12035, P12036, P13647, P13648, P15241, P16884, P19013, P19246, P19527, P21619, P21910, P25691, P35908, P48671, P48672, P48678, P48679, P78385

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

94 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	78
Likely benign	3
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1251 predictions. Top by Δscore:

Variant	Effect	Δscore
12:52172193:CTCA:C	donor_loss	1.0000
12:52172194:TCAC:T	donor_loss	1.0000
12:52172196:AC:A	donor_loss	1.0000
12:52172197:CCT:C	donor_loss	1.0000
12:52172223:T:TA	donor_gain	1.0000
12:52172414:AGGCA:A	acceptor_gain	1.0000
12:52172415:GGCA:G	acceptor_gain	1.0000
12:52172416:GCA:G	acceptor_gain	1.0000
12:52172417:CA:C	acceptor_gain	1.0000
12:52172417:CAC:C	acceptor_gain	1.0000
12:52172419:C:CC	acceptor_gain	1.0000
12:52172419:C:CG	acceptor_loss	1.0000
12:52172420:T:A	acceptor_loss	1.0000
12:52172422:C:CT	acceptor_gain	1.0000
12:52172423:A:T	acceptor_gain	1.0000
12:52172426:C:CT	acceptor_gain	1.0000
12:52172426:C:T	acceptor_gain	1.0000
12:52172427:A:T	acceptor_gain	1.0000
12:52173032:A:AC	donor_gain	1.0000
12:52173033:C:CC	donor_gain	1.0000
12:52173034:TCA:T	donor_loss	1.0000
12:52173036:A:AC	donor_gain	1.0000
12:52173037:C:CT	donor_gain	1.0000
12:52173037:CA:C	donor_gain	1.0000
12:52173037:CAT:C	donor_gain	1.0000
12:52173037:CATG:C	donor_gain	1.0000
12:52173037:CATGG:C	donor_gain	1.0000
12:52173159:TCCAG:T	acceptor_gain	1.0000
12:52173160:CCAG:C	acceptor_gain	1.0000
12:52173160:CCAGC:C	acceptor_gain	1.0000

AlphaMissense

2947 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:52180906:C:A	K189N	0.991
12:52180906:C:G	K189N	0.991
12:52180940:C:G	R178P	0.982
12:52173090:A:G	L302P	0.978
12:52191621:A:C	F94L	0.977
12:52191621:A:T	F94L	0.977
12:52191623:A:G	F94L	0.977
12:52180910:A:G	L188P	0.974
12:52180924:G:C	F183L	0.974
12:52180924:G:T	F183L	0.974
12:52180926:A:G	F183L	0.974
12:52173066:C:G	R310P	0.973
12:52173069:A:G	L309P	0.973
12:52173623:C:G	A270P	0.971
12:52180604:A:G	L192P	0.969
12:52180583:C:G	R199P	0.968
12:52172355:C:G	A341P	0.965
12:52185418:A:G	L157P	0.962
12:52180574:A:G	L202P	0.960
12:52180907:T:G	K189T	0.960
12:52172270:A:G	L369P	0.959
12:52172388:C:G	A330P	0.959
12:52185385:C:G	R168P	0.956
12:52173751:A:G	L227P	0.954
12:52180918:A:C	F185L	0.951
12:52180918:A:T	F185L	0.951
12:52180920:A:G	F185L	0.951
12:52185568:C:G	R107P	0.947
12:52191622:A:C	F94C	0.946
12:52173760:A:G	L224P	0.945

dbSNP variants (sampled 300 via entrez): RS1000021514 (12:52181571 G>A), RS1000122956 (12:52186607 C>T), RS1000154114 (12:52186902 C>A), RS1000182835 (12:52190095 G>A,T), RS1000328087 (12:52192022 A>G), RS1000341502 (12:52170460 T>A,G), RS1000380979 (12:52170559 A>C), RS1000390758 (12:52184965 C>T), RS1000783541 (12:52191331 G>T), RS1000845820 (12:52192227 G>A,C), RS1000922609 (12:52173317 C>G), RS1001069909 (12:52191033 C>T), RS1001079608 (12:52178726 G>A), RS1001180759 (12:52190971 G>A), RS1001237460 (12:52188291 A>T)

Disease associations

OMIM: gene MIM:611161 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST002341_2	Telomere length	7.000000e-06
GCST002875_139	Diisocyanate-induced asthma	1.000000e-06
GCST011739_7	Cutaneous leishmaniasis	7.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0006995	response to diisocyanate

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

68 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
(+)-JQ1 compound	decreases expression	3
sodium arsenite	affects cotreatment, increases abundance, decreases expression	2
perfluorooctane sulfonic acid	decreases expression, increases expression	2
Arsenic	affects cotreatment, decreases expression, increases abundance	2
Estradiol	affects cotreatment, decreases expression, increases expression	2
Valproic Acid	increases expression, increases methylation	2
Cyclosporine	decreases expression, increases expression	2
Aflatoxin B1	increases expression	2
Particulate Matter	affects cotreatment, decreases expression, increases abundance, increases expression	2
aristolochic acid I	increases expression	1
propionaldehyde	increases expression	1
lead acetate	decreases expression	1
sodium arsenate	decreases expression, increases abundance	1
pyrogallol 1,3-dimethyl ether	affects localization, decreases expression, increases expression, affects cotreatment	1
ethyl-p-hydroxybenzoate	increases expression	1
sulforaphane	decreases expression	1
butyraldehyde	increases expression	1
manganese chloride	increases abundance, affects cotreatment, decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
hydroquinone	increases expression	1
S-(1,2-dichlorovinyl)cysteine	decreases expression, affects cotreatment	1
pentanal	increases expression	1
polyhexamethyleneguanidine	affects expression	1
abrine	increases expression	1
archazolid B	decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
NSC 689534	affects binding, increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Temozolomide	increases expression	1
Sunitinib	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.